2019 International Congress Archives - Page 172 of 217

Safety and Tolerability in Parkinson’s Disease Patients Treated with a Continuous Subcutaneous Infusion of ABBV-951: Design of a 52-Week Phase 3 Study

M. Facheris, J. Benesh, J. Streit, W. Robieson, C. Zadikoff, D. Standaert (North Chicago, IL, USA)
Safety and Tolerability of Apomorphine Sublingual Film During Maintenance Treatment in Patients With Parkinson’s Disease and “OFF” Episodes: A Pooled Analysis

W. Ondo, A. Ellenbogen, S. Isaacson, A. Espay, C. Singer, P. Bhargava, M. Worden, D. Blum, B. Navia (Houston, TX, USA)
Safety and Tolerability of opicapone in Parkinson’s disease

M. Campins Romeu, M. Losada López, I. Sastre Bataller, MJ. Pérez García, I. Martínez Torres (Valencia, Spain)
Safety of Bone marrow-derived Allogeneic Mesenchymal Stem Cells in Parkinson’s disease Patients

M. Schiess, J. Suescun, T. Ellmore, MF. Doursout, E. Furr -Stimming, Z. Mei, A. Gee (Houston, TX, USA)
Safety of Gocovri in Clinical Practice: One-year Post-launch Pharmacovigilance Data

C. Tanner, R. Pahwa, V. Vandevoorde, K. Wehrman, R. Elfont (San Francisco, CA, USA)
Safety of Iron Chelation in Patients with Brain Iron Overload

C. Fradette, T. Klopstock, L. Neumayr, I. Karin, G. Zorzi, T. Kmieć, B. Büchner, H. Steele, R. Horvath, P. Chinnery, A. Basu, C. Küpper, C. Neuhofer, F. Zibordi, N. Nardocci, A. Stilman, M. Spino, E. Vichinsky, F. Tricta (Toronto, ON, Canada)
Safinamide ameliorates motor deficits and plastic alterations before the onset of L-DOPA-induced dyskinesia in a rat model of Parkinson’s disease

M. Sciaccaluga, P. Mazzocchetti, G. Bastioli, V. Ghiglieri, B. Picconi, A. Tozzi, C. Caccia, C. Keywood, G. Padoani, P. Calabresi (Perugia, Italy)
Safinamide improves motor symptoms severity and daily living in Parkinson’s Disease (PD) patients

C. Cattaneo, E. Bonizzoni, C. Keywood (Milan, Italy)
SAFINAMIDE IN DAILY CLINICAL PRACTICE: ASSESSMENT OF EFFICACY AND TOLERABILITY IN PARKINSON´S DISEASE

A. Vinagre-Aragón, E. Mondragón-Rezola, I. Croitoru, A. Bergareche-Yarza, JJ. Poza-Aldea, A. Olaskoaga-Caballer, M. Iridoy-Zulet, M. Ruibal-Salgado, JC. Gómez-Esteban, K. Berganzo-Corrales, B. Tijero-Merino, J. Ruiz-Martínez (San Sebastián, Spain)
Safinamide in the treatment of URINARY symptoms in PARKinson’s disease (SURINPARK)

A. Gómez López, I. Pareés Moreno, S. Fanjul Arbós, JL. López Sendon, JC. Martínez Castrillo, A. Alonso Cánovas (Madrid, Spain)